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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) 
are relapsing and remitting chronic inflammatory 
conditions that fall under the umbrella term of 
inflammatory bowel diseases (IBD). Both disor-
ders generally tend to become apparent in people 
between the age of 20 and 40 years. The preva-
lence of IBD in the UK is 0.5–1% with an esti-
mated 620,000 people thought to be affected.1 
Although there are methods of inducing remission 
in both diseases, currently neither are curable.
IBD are multifactorial. The exact aetiology is 
incompletely understood, but it is thought to 
involve the complex interaction between a 
patient’s genetic predisposition, environment, gut 
microbiota and immune system. To date, when 
studying these components in isolation, each has 
shown changes that are associated with CD and 
UC, but it has not generally been possible to 
directly link any of these factors in isolation as a 
cause of IBD. This disconnect leads us to con-
clude that these components form intricate and 
complex interactions that contribute both to the 
initiation and maintenance of the intestinal 
inflammation that typifies IBD.
Specific interest in the contribution of the gut 
microbiota to IBD has been growing. It has been 
established that perturbation of the structure of 
the gut microbiota has been linked to intestinal 
inflammation.2 Characteristic findings include a 
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decrease in bacterial diversity and richness3–6  
and a decrease in temporal stability.7 Further-
more, key changes have been identified in IBD 
such as a reduction in species derived from the 
Firmicutes phylum (such as Faecalibacterium praus-
nitzii8) and increases in species derived from 
Proteobacteria (including members of the family 
Enterobacteriaceae9,10). Currently, it is not under-
stood whether perturbation of the structure of the 
gut microbiota is the cause of, or the result of, 
intestinal inflammation.
Before the utilization of systems biology tech-
niques, our knowledge regarding the gut micro-
biota was limited to culture-based techniques, 
which are labour-intensive and not high-through-
put. In particular, they require specific conditions 
to optimize bacterial growth (e.g. an anaerobic 
environment and selective media for each spe-
cies). Despite these limitations, however, Browne 
and colleagues created a workflow that demon-
strated that by using a complex, broad range bac-
teriological medium, it was possible to archive 
bacteria representing 96% of the bacterial abun-
dance at the genus level and 90% of the bacterial 
abundance at the species level.11
Despite such advancements in culturing tech-
niques, they remain limited by their inability to 
detect other key microbiome components, such 
as the virome, mycobiome and archaea. However, 
recent advancements in high-throughput ‘omic’ 
systems biology techniques, designed to detect 
the entire spectrum of particular components 
under scrutiny in biofluids or tissues, have given 
novel insight into the structure and function of 
the gut microbiota.
To begin to understand the complexity of each of 
these components that contribute to IBD, novel 
techniques have been utilized to begin to under-
stand their function on a different level. Through 
the use of bioinformatics pipelines, we are increas-
ingly able to analyze biological molecules and 
profile microorganisms in greater detail than ever 
before. The development of novel systems biology 
techniques - including genomics, metabonomics, 
transcriptomics and proteomics - presents a new 
frontier in attempts to understand the complex 
interactions and the multifactorial nature of IBD. 
These ‘omic’ technologies allow us direct analysis 
of members of the microbiota, their genes, tran-
scripts, metabolites and proteins from biological 
samples, which overcomes the bias and limitation 
of previous culture techniques, but sometimes 
brings new biases and challenges.
These systems biology platforms provide us with 
not only details about compositional changes in 
IBD, but in particular give us a better compre-
hension of the functional alterations that may 
contribute to IBD. Such techniques provide 
exciting technology that may help us understand 
the underlying cause for IBD, as well as high-
light predictors of disease and novel therapeutic 
markers.
Systems biology platform studies can be per-
formed on both the host and the microbiota com-
munity. Specific examples of omic studies in the 
host are genomic studies, the mostly widely stud-
ied omic studies in IBD, which have identified up 
to 163 IBD-specific loci.12 Despite this advance-
ment in genomics, as yet their impact on disease 
pathways remains unclear, suggesting that genet-
ics contribute to but do not entirely account for 
the development of IBD. Genomics is the study 
of the ‘static’ DNA of a host, while transcriptom-
ics is the study of the dynamic expression of RNA 
molecules and how they may vary under different 
circumstances. This approach therefore allows us 
to study the genes that are actively expressed at 
any given time and circumstance.13 Specific pro-
gress investigating transcriptomics in the host has 
highlighted that protein-coding and noncoding 
RNA such as micro RNA have a role in immune 
regulation in IBD.14–20 Furthermore, through 
host transcriptomics, potential microRNAs have 
been highlighted as potential biomarkers of 
IBD.17,21
This review will focus on the use of systems biol-
ogy technologies to better understand the nature of 
microbial communities. We will summarize our 
knowledge to date regarding omics in IBD and 
their role in understanding the gut microbiota (also 
see summary in Table 1 and Figure 1).
Metagenomics and metataxonomics
The advent of next generation sequencing 
(NGS) in the last decade has facilitated a 
remarkable insight into the characteristics and 
functionality of the gut microbiome with unprec-
edented throughput and resolution. The first 
critical studies set the baseline by defining the 
diversity and composition of the gut microbiota 
from stool samples or colonic biopsies from 
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healthy individuals.22 Intriguingly, they revealed 
that nearly 70–80% of the bacteria inhabiting 
the human gut were previously unknown and 
were thus considered ‘unculturable’ at that 
time.11,23 Further studies then began to explore 
the differences in the gut microbiome in health 
and disease states while elucidating potential 
host–microbiome interactions and pathophysio-
logical mechanisms.
Metataxonomics: 16S rRNA gene sequencing and 
analysis. Most of the culture-independent char-
acterization of the gut microbiome in IBD has 
been directed towards sequencing of 16S rRNA 
genes, which are present in all cellular organ-
isms.24 This gene was chosen as it is relatively 
small (∼1.5  kb) and has a highly significant level 
of sequence conservation between bacterial spe-
cies to facilitate reliable and robust alignments 
with sufficient variation to infer evolutionary rela-
tionships. Through barcoded primer sets that tar-
get highly conserved regions of the 16S rRNA 
gene, metataxonomics seeks to amplify and subse-
quently sequence the hypervariable regions of the 
gene from bacteria and archaea within a given 
sample.25 The sequences are clustered into phylo-
types according to their likeness to previously 
annotated sequences in a reference database or 
constructed into operational taxonomic units 
(OTUs) by clustering sequences based on their 
similarity.26
Metataxonomics provides a highly cost effective 
and rapid means of defining microbial commu-
nity (16S rRNA genes for bacteria and 18S rRNA 
genes for eukaryotes) richness and semi-quantita-
tive relative taxonomic abundance data.27 It also 
remains the primary technique for untargeted 
characterization of mucosally-adherent bacteria 
in the colon or other tissues that have a relatively 
low bacterial biomass. This technique is however 
known to be limited by the challenges associated 
with polymerase chain reaction (PCR)-based 
short read length sequencing including GC 
bias, sequencing errors and difficulties in assess-
ing OTUs.28 Furthermore the characterization of 
closely related species by 16S rRNA gene is lim-
ited and resolution rarely differentiates strains of 
the same species. However, third generation 
approaches are starting to open up the possibility 
of species and strain-level metataxonomic 
approaches by combining the MinIon platform 
and longer amplicons.29 Unlike metagenomics, 
insights into the metabolic potential of a 
community cannot be obtained through a met-
ataxonomic approach. Bioinformatics pipelines 
such as PICRUSt and Tax4Fun, however, allow 
predictions of the functional capability of a com-
munity based on a 16S rRNA gene dataset with 
significant metagenome correlation for biosam-
ples obtained from the lower gastrointestinal (GI) 
tract.30,31
Metagenomics. Metagenomics or ‘shotgun 
metagenomics’, refers to the untargeted sequenc-
ing of whole-community DNA in an environ-
ment.32 In a sample such as stool that consists of 
a complex microbial community, shotgun 
sequencing is primarily used to profile its taxo-
nomic composition (down to the strain level) and 
directly identify functional potential. Unlike 
metataxonomics, rather than targeting a specific 
marker gene for amplification, all the extracted 
DNA in a given sample is sheared into small frag-
ments, barcoded and independently sequenced.33 
The resulting DNA sequences (or reads) are 
either assembled or left unassembled, and aligned 
to databases to provide accurate quantitative tax-
onomic and functional characterization. Conse-
quently, metagenomics provides the opportunity 
to simultaneously explore two aspects of a micro-
bial community; exactly who is there and what 
they are potentially capable of doing.
Metagenomics has enabled large-scale investiga-
tions of complex microbiomes and helped under-
stand functional differences in healthy and 
diseased states. It provides strain-level resolution 
of gut bacteria and additionally characterizes non-
bacterial microbial communities such as fungi and 
viruses that have recently been shown to poten-
tially play a crucial role in host health.34,35 This 
technique, although powerful, does have many 
limitations: relatively, it is significantly more 
expensive than 16S rRNA gene sequencing; fur-
thermore, there are many incompletely annotated 
bacterial genomic sequences, and uncertainties 
about the accuracy and even coverage of data-
bases. As metagenomics bioinformatics tools rely 
on availability of annotated genomes they are 
therefore affected by limitations in reference 
sequence databases. Moreover, lack of annota-
tions for a large number of microbial species when 
profiling metabolic potential leads to a bias 
towards highly conserved pathways (such as 
housekeeping genes), even when there are signifi-
cant differences in the taxonomic composition.33,36 
Furthermore, the lack of host DNA depletion kits 
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mean metagenomics is not reliable on tissues 
with low host–microbe biomass ratio, such as 
colon biopsies, where >95% of DNA sequenced 
is nonmicrobial.
Metataxonomic and metagenomic insights into 
IBD. Gut microbial taxonomic and functional pro-
filing studies of stool and mucosal biopsies through 
NGS has provided us with a wealth of evidence 
that a dysfunctional gut microbiome plays a crucial 
role in the pathogenesis of IBD.10,37 There are con-
sistent data demonstrating that patients with IBD 
have a decrease in the compositional diversity and 
stability largely due to a reduction in the phylum 
Firmicutes and an increase in Proteobacteria.38–40 
Shifts in specific taxonomic classes have been con-
sistently reported in IBD. Broadly, gut bacterial 
classification studies in IBD have identified deple-
tions in bacteria with anti-inflammatory effects, 
including Bifidobacterium, Lactobacillus, Faecalibac-
terium prausnitzii and other short-chain fatty acid 
(SCFA)-producing bacteria, along with a relative 
expansion in pathogenic bacteria, including Proteo-
bacteria such as adherent-invasive Escherichia 
coli.38,41–43 These compositional differences high-
light potential mechanisms that contribute to the 
inflammatory mechanisms of disease in IBD. For 
example in several landmark studies, reduced 
abundances of ileal mucosal F. prausnitzii are asso-
ciated with a higher risk of recurrent CD after ileo-
caecal resection, and recovery of F. prausnitzii after 
a flare in UC is associated with maintenance of 
clinical remission.42 Metagenomic studies have 
further highlighted differences in the functional 
composition of the gut microbiota in IBD.9 Genes 
associated with butanoate and propanoate metab-
olism are decreased and this change is consistent 
with the reductions seen in SCFA-producing Fir-
micutes clades from studies profiling gut bacterial 
taxonomy. Furthermore, a decrease in genes asso-
ciated with the biosynthesis of amino acids and an 
increase in amino acid transporters and metabo-
lism of the sulfur-containing amino acid cysteine is 
noted amongst many findings.
Metagenomics and metataxonomic studies (in 
conjunction with other microbial omics) highlight 
multiple potential pathways through which gut 
microbiota in IBD contribute to immune dysregu-
lation, gut barrier breakdown and intestinal 
inflammation. There are significant inter-study 
discrepancies largely due to multiple confounding 
factors, such as tissue source (stool or mucosa), 
disease activity, medication, diet, age and 
differences in both wet and dry lab techniques. On 
its own, this microbial compositional and func-
tional profiling in IBD has only demonstrated dis-
ease associations and potential mechanisms.44,45 
We now need well designed studies in IBD that 
use metagenomics or metataxonomics as one part 
of the jigsaw in proving causative mechanisms and 
predicting or ameliorating disease.
Metatranscriptomics
The recent emergence of highly parallel RNA-
sequencing technologies has allowed us to gain 
insights into gene expression profiles of the host 
and microbial community. While metagenomics 
tells about the genomic potential of microbes in a 
community, metatranscriptomics informs us on 
the actual genetic activity within a community 
phenotype. The gut microbial transcriptional 
activity is determined by a multitude of factors 
such as changes in host health and disease state, 
immune micro-environment, diet and the micro-
bial ecosystem. The metatranscriptome, there-
fore, is dynamic and contextualizes microbial 
functional activity to the host phenotype, and 
when used in conjunction with metagenomics 
provides a powerful understanding on the molec-
ular mechanisms by which gut bacteria contribute 
to health and disease.46–48 It provides significant 
value in shifting our current descriptive gut micro-
biome knowledge towards a deeper understand-
ing of host–microbial causal mechanisms in 
contributing to homeostasis and disease.
A metatranscriptome experiment involves isolation 
of total RNA from a tissue, such as colon biopsy or 
stool. This isolation can be followed by depletion of 
the host mRNA, for example, by using hybridiza-
tion probes that take advantage of the poly-A tail on 
eukaryotic mRNA. In eukaryotic and prokaryotic 
cells, approximately 80–90% of the total RNA is 
comprised of ribosomal RNA (rRNA) and 15% of 
transfer RNA (tRNA); protein-coding mRNA con-
stitutes only 2–5% in a sample.49 Consequently, 
this makes depletion of both human and bacterial 
small and large rRNA an imperative step of any 
metatranscriptome experiment.50 Libraries of 
cDNA from the rRNA-depleted mRNA are gener-
ated followed by ligation to adapters before ampli-
fication and sequencing. Bioinformatic pipelines 
such as HumaNN2 and SAMSA2 can be used to 
process the generated reads, perform quality con-
trol assessment, and undertake removal in silico of 
any rRNA and host transcriptome contamination. 
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The filtered sequences are then aligned to a micro-
bial translated protein sequence such as the UniProt 
database and functional databases such as KEGG 
or SEED.
There are several major limitations of metatran-
scriptomics. Tissues such as colonic biopsies con-
sist of a significant amount of host contamination 
where host cells make up nearly 95% of the bio-
mass. Such cases require deep sequencing of the 
total mRNA in order to obtain a representative 
window into the mucosally-adherent microbial 
gene expression profile.46 The microbial transcrip-
tome or translated protein databases are not com-
prehensive and consist of a large number of genes 
that are currently not yet annotated to a known 
function. This knowledge gap often leads to an 
incomplete, and to a certain extent, biased inter-
pretation of the microbial functional profile, but is 
likely to change as this field evolves over time.
Metatranscriptomics in IBD. As metatranscrip-
tomics is a relatively new technology, there is a 
paucity of data for gut microbial transcriptomic 
profiling in health or any given disease. The largest 
faecal metatranscriptome study in IBD was con-
ducted as part of the Integrative Human Microbi-
ome project (IBD multi’omics database).51 In this 
study, metagenomic analysis was paired with 
metatranscriptomic analysis from 117 individuals 
(24 non-IBD healthy controls, 59 patients with 
CD, 34 with UC). They found that the gut micro-
bial functional potential (based on metagenomics) 
is often but not always proportional to metatran-
scriptomic profiles. Multiple metabolic pathways 
were found to be differentially expressed, such as 
the methylerythritol phosphate pathway predomi-
nantly by Alistipes putredinis and dTDP-L-rham-
nose biosynthesis by F. prausnitzii. These pathways 
are associated with inducing or regulating inflam-
mation, immune response and altering interspe-
cies interactions in the gut. This study represented 
the first step towards a new way of interpreting 
‘dysbiosis’ in IBD by going beyond microbial 
compositional profiling and contextualizing 
altered microbial gene expression in relation to 
disease. The field of metatranscriptomics will con-
tinue to evolve our understanding of host–micro-
biome relationship in IBD in the coming years.52
Metaproteomics
Metaproteomics involves the high-throughput 
characterization of the entire constituent profile 
of microbial proteins within a biofluid or tissue 
sample. A key utility of metaproteomic studies is 
that the identification of the protein content of a 
sample, coupled with insight to their interactions, 
abundances, and modifications, gives direct infor-
mation about the true functional activity of the 
gut microbiota. As already discussed, this level of 
functional insight is not typically captured by 
studies focused on microbial sequencing alone. A 
range of different methodologies may be used for 
proteomic studies, including both gel-based and 
gel-free techniques, mass spectrometry, nuclear 
magnetic resonance, and microarray-based 
technologies.53,54
However, as for other omics technologies, there 
are potential limitations that must be considered 
when performing and interpreting proteomic 
studies. The proteome is vast in its scale and com-
plexity (with proteins often interacting in networks 
rather than functioning singularly), which trans-
lates to high complexity in the processing and 
analysis of proteomic data. While the Human 
Proteome Project database (https://hupo.org/human 
-proteome-project) is available to researchers, 
there are no definitive reference metaproteomic 
databases available at present. Differences exist 
between proteome profiles established using alter-
nate methodologies or after analysis in different 
laboratories.55 There are disparities between the 
metaproteome of gut mucus, luminal content and 
faecal material56
Metaproteomics in IBD. While metaproteomics as 
applied to IBD is a relatively novel field, there are 
a growing number of studies in which it has been 
applied. In one of the first such investigations, dif-
ferent stool metaproteome profiles were observed 
between human patients with CD in comparison 
with healthy individuals, with patients with CD 
(and particularly with those with the disease in an 
ileal distribution) having a particular depletion of 
a large range of microbial proteins.57 A further 
area in which metaproteomics has been applied 
has been in the analysis of the mucosal-luminal 
interface, with the aim of better elucidating any 
aberrations in gut microbiota–host interactions 
that may contribute to the onset or activity level 
of IBD. A study from Li and colleagues identified 
distinct protein modules at the mucosal-luminal 
interface; these differed between healthy controls 
and patients with IBD, and, in the case of certain 
modules, differentiated UC from CD.58 Metapro-
teomic analysis on the mucosal-luminal interface 
Therapeutic Advances in Gastroenterology 12
6 journals.sagepub.com/home/tag
has also recently been reported for a paediatric 
IBD inception cohort59 This demonstrated upreg-
ulation of microbial proteins related to oxidative 
stress responses in children with IBD compared 
with controls. In addition, the expression of 
human proteins related to oxidative antimicrobial 
activities was also increased in IBD cases and cor-
related with the identified changes in microbial 
functions.
Metabolomics and metabonomics
Metabolomics is defined as the quantitative meas-
urement of the dynamic multi-parametric meta-
bolic response of living systems to 
pathophysiological stimuli or genetic modifica-
tion.60 Metabonomics is defined as ‘the quantita-
tive measurement over time of the metabolic 
responses of an individual or population to drug 
treatment or other intervention’.61 Despite often 
being used interchangeably, the subtle differences 
are that metabolomics places a greater emphasis 
upon metabolic profiling on a cellular or organ 
level, while metabonomics extends to metabolic 
profiling that includes the contributions of envi-
ronmental influences such as diet, toxins, drugs 
and the gut microbiota.62 A key importance of 
metabonomics is using an integrated systems 
biology approach which provides a way of investi-
gating the metabolic status of an organism or eco-
system by studying ‘real’ metabolic endpoints.62
Metabonomics can be used to predict responses to 
medical treatment (termed pharmacometabonom-
ics),63 as well in the prediction of diseased states, 
raising the potential for personalized medicine.64,65 
This integrated technology utilizes 1H-nuclear 
magnetic resonance (NMR) and mass spectrome-
try (MS), which is split into liquid chromatogra-
phy-MS (LC-MS) and gas chromatography-MS 
(GC-MS). There is also a growing interest in 
ambulatory MS techniques, such as rapid evapora-
tive ionization MS (REIMS) and desorption MS 
imaging (DESI)66–68 Complex multivariate statisti-
cal models and bioinformatics are used to enable 
interpretation of metabolic profiling data.
Metabonomics therefore enables profiling of the 
unique end product or metabolites found in bio-
fluids. This can enable longitudinal assessment of 
metabolic changes, metabolic changes in response 
to treatment and metabolic profiles in both 
healthy and diseased states. Metabonomic profil-
ing can provide insights into unique fingerprints 
of biochemical perturbations that are characteris-
tic of a disease process.69 This can therefore be 
the basis of finding novel biomarkers.
Metabonomics in IBD. The unique advantage of 
metabonomics is that it can link metabolites found to 
specific metabolic pathways which can directly link in 
with the bacterial metabolic pathways, therefore 
advancing the interplay of the microbiota and meta-
bolic pathways on disease aetiology. For instance, it 
has been shown that there are low levels of hippurate 
(a metabolite that is derived from the gut microbiota) 
in the urine of patients with IBD. This finding is of 
interest as hippurate levels have been shown to cor-
relate with the presence of Clostridia in the gut.70 Fur-
thermore, Williams and colleagues, using NMR 
profiling, found that significant decreases in urinary 
hippurate were found in patients with IBD.71
Serum has been another biofluid that has been 
analyzed in IBD.72–75 Despite differences being 
shown between amino acids and and molecules of 
the tricarboxylic acid (TCA) cycle between UC 
and CD74,75 as a tightly regulated biofluid, the 
ability to discriminate between UC and CD is 
reduced. It is also likely that due to homeostatic 
regulation and that the fact that serum is not 
directly in contact with the gut microbiota, this 
biofluid is less likely to be able to provide infor-
mation on important changes in the gut microbi-
ota through metabonomic processing.
The dysbiosis found in IBD has created a lot of 
interest in the metabolic profiling of faeces. 
Marchesi and colleagues highlighted that patients 
with IBD showed a lower level of faecal SCFAs 
when compared with healthy people through 
NMR profiling.76 Specifically, they found that a 
depletion in SCFAs including acetate and butyrate 
in patients with CD when compared with healthy 
people. The SCFAs are mainly produced by the 
fermentation of complex carbohydrates via the gut 
bacteria. Furthermore, they found that methyl-
amine and trimethylamine were decreased in 
patients with CD. In trying to link to the gut micro-
biota, it has been shown that these two compounds 
are derived from intestinal degradation of food 
components such as choline and carnitine by 
microbiota.77 The role of SCFAs was supported by 
Le Gall and colleagues, who reported that butyrate 
and acetate were reduced in CD when compared 
with healthy people; they also found elevated levels 
of taurine in active UC when compared with 
healthy people and suggested that this could be 
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high due to the gut microbiota’s role in the decon-
jugation of bile acids.78 Further work on faeces was 
performed by Jansson and colleagues who found 
that patients with ileal CD had a greater abun-
dance of Bacteroides vulgatus (BV), B. ovatus (BO) 
and E. coli when compared with healthy people 
which correlated most strongly to bile acids, 
including taurocholic and cholic acids, and fatty 
acids, including stearic and docosapentanoic acids, 
and concluded that there are correlations between 
metabolites and the bacterial microbiota but cau-
sality will need further exploration.79
Tissue is another source of material that can be 
analyzed using metabonomics. It is one of the less 
studied. Sharma and colleagues highlighted that 
the metabolic profile of amino acid membrane 
components and lactate were similar between 
noninflamed IBD segments and inflamed seg-
ments.80 Bjerrum and colleagues reported that 
colonic biopsies from patients with active UC had 
higher levels of antioxidants and a range of amino 
acids, but lower levels of lipid, glycerophospho-
choline (GPC), myo-inositol, and betaine when 
compared with healthy people. Whilst both these 
studies suggest mechanistic pathways, neither 
integrated metabonomic with microbiota data.
Omics data integration methods
Integrating the omics is challenging because of 
multiple types of data set, but the process is 
improving. Each of the omic data sets convey 
knowledge from different labels (layers) of the 
molecular organization; for example, gene expres-
sion is about genes that changes globally but also 
those that change significantly between diseases 
versus controls (for example IBD and non-IBD 
patients). Other omic data sets (such as meta-
bonomics, lipidomics, metagenomics, and micro-
biome) also provide similar types of knowledge. 
Linking, fusing or integrating (Figure 2) those 
multi-omics matrices provides a holistic picture 
of the disease versus control patients in terms of 
the mechanistic understanding of the disease 
state. Multi-omics data usually consist of two or 
more matrices (for example, transcriptomics and 
metabonomics, metabonomics and microbiome, 
lipidomics and transcriptomics, metabonomics 
and proteomics) that share the same patients 
(sample numbers or same objects) but contain 
different biological features (variables) such as 
genes, metabolites, lipids or OTUs.
Univariate versus multivariate methods. Differ-
ent statistical approaches - specifically, univariate 
Table 1. Summary of changes in IBD using a systems biology approach when compared with healthy people.
Metagenomics •  Genes associated with butanoate and propanoate metabolism genes are 
decreased in IBD
•  Decrease in genes associated with the biosynthesis of amino acids and an 
increase in amino acid transporters and metabolism of the sulfur containing 
amino acid cysteine in IBD
Metataxonomics •  Depletion of bacteria with anti-inflammatory effects, including Bifidobacterium, 
Lactobacillus, Faecalibacterium prausnitzii and other SCFA-producing bacteria
•  Relative expansion in pathogenic bacteria, including Proteobacteria such as 
adherent-invasive Escherichia coli
Metatranscriptomics •  Gut microbial functional potential (based on metagenomics) is often but not 
always proportional to metatranscriptomic profiles.
•  Multiple metabolic pathways were found to be differentially expressed such as 
methylerythritol phosphate pathway predominantly by Alistipes putredinis and 
dTDP-L-rhamnose biosynthesis by F. prausnitzii
Metaproteomics •  Depletion of a large range of microbial proteins (Crohn’s disease, especially 
ileal disease)
•  Distinct protein modules at the mucosal-luminal interface differed between 
healthy controls and patients with IBD
Metabonomics • IBD patients have low urinary hippurate levels
• IBD patients have lower levels of faecal short-chain fatty acids
• Specifically, stool butyrate and acetate were reduced in Crohn’s disease
IBD, inflammatory bowel disease; SCFA, short-chain fatty acid.
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or multivariate analyses - are applied to under-
stand associations (or correlations) between bio-
logical features (variables) in different omic data 
sets. In the literature there are many methods 
described starting from simple univariate to 
multivariate methods to determine if there are 
relationships between individual genes, metabo-
lites, lipids or OTUs (microbiome). In the liter-
ature both parametric and nonparametric 
univariate methods have been applied to link 
OTUs and metabolomics data. Some examples 
are that where Theriot and colleagues performed 
univariate nonparametric correlation analysis 
(Spearman correlation analysis) between micro-
biome and metabolomics data from the mouse 
gut to identify relationships between features 
(metabolite versus taxonomic features or 
OTUs)81,82, and work by Mao and colleagues,83 
who used parametric correlation analysis (Pear-
son correlation analysis) to find associations 
between taxonomic features or OTUs and 
metabolites.82,83 A major advantage of the uni-
variate correlation is that those methods are 
easy to understand as they are simple models, 
but they do not take into account the correlation 
structure of the data. Multivariate approaches, 
on the other hand, take into account the correla-
tion (association) structure of the omic data 
sets, but suffer from high dimensionality of the 
data. Such high dimensionality is caused by the 
number of features from any type of omic data 
set. In the high dimensional settings, we have 
two issues or challenges:
(a)  The number of parameters, features or vari-
ables (p) are large compared with the num-
ber of the samples, experimental units or 
individuals (n), in high dimensional statis-
tics known as p>>n (large ‘p’ small ‘n’ prob-
lem) and due to that, is not possible to apply 
many statistical models, such as multiple 
linear regression.
(b)  The features, variables or parameters are 
correlated.
To overcome the above problems, researchers 
have suggested some tentative solutions, for exam-
ple, to create a new feature called a latent feature, 
using a linear combination of the original varia-
bles. Such approaches are called dimension reduc-
tion methods. Omic data sets are usually taken 
into account together to find out joint variations in 
the features. Some of the methods include partial 
least squares regression (PLS)84 and two-way 
orthogonal partial least squares analysis 
(O2PLS).85,86 Aidy and colleagues87 used O2PLS 
to connect transcriptomics, metabolomics and 
microbiome. Morgan and colleagues used linear 
discriminant analysis to link host transcriptomics, 
microbiome and clinical data.88 Canonical corre-
lation analysis (CCA)89 is another type of method 
that maximizes the correlation structure of the two 
omic data sets, for example, metabolomics and 
proteomics. Recently, in the literature many ver-
sions of the CCA appeared; for example Sparse 
CCA90 and Kernel CCA91 tools have been devel-
oped38 with statistical methods like PLS, O2PLS 
Metagenomics MetaproteomicsMetabonomicsMetatranscriptomicsMetataxonomics
V4
V4
Untargeted sequencing of 
DNA in an environment for 
strain level resoluon and 
potenal community funcon
Amplificaon and sequence 
of the hypervariable regions 
of the 16S gene from bacteria 
and archaea in a sample
Sequencing of microbial RNA 
that informs us on the actual 
genec acvity within a 
community phenotype
High-throughput characterisaon 
of the enre constuent profile 
of microbial proteins within a 
biofluid or ssue sample
The quantave measurement 
over me of the metabolic 
responses of an individual or 
populaon to drug treatment 
or other intervenon
*
*Metaproteomic plot adapted 
from Xiaoxiao Li et al. Cell Mol
Gastroenterol Hepatol. 2016 Sep; 
2(5): 567–583. 
Figure 1. Summary of systems biology platforms.
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and CCA included in the packages. An example is 
Mixomics (R version 6.32) that aims to help draw 
the variable omics together to create a logical inte-
grative story. Acharjee and colleagues,92 devel-
oped omicsFusion, which is a web application that 
can perform statistical analysis based on regulari-
zation93,94 like LASSO 93 and Elastic net94 together 
with univariate regression and dimension reduc-
tion methods.
The other type of integration is treating each of 
the omics data separately with a clinical outcome 
and selecting important features from them and 
integrating. Procedures for selecting subsets of 
features/variables are called variable or feature 
selection procedures. By doing this, it is possible 
to reduce the dimensionality of the data set and 
perhaps to get rid of some or even many noise 
variables (variables that have no predictive power 
for the response variable) in the data set.
Therefore, such type of integration is essentially 
integration of two labels. This integration pro-
vides us with two types of information: first, the 
type of the omics data, which is important for 
future experiments; and second, features that are 
important for prediction. Acharjee and col-
leagues95 used a random forest approach to select-
ing features from metabolomics and lipidomics 
data and linked these with clinical outcomes in 
mouse data sets. Furthermore, Acharjee and col-
leagues96 used a similar approach to integrate 
transcriptomics and metabolomics/metabonomic 
data in plant species.
Conclusion
This review has highlighted the potential of omics 
to integrate all the various variables that contrib-
ute to IBD to enable us to begin to understand 
their interactions within the gut microbiota. It is 
important to highlight that as well as integrating 
the known omics, future studies need to integrate 
the role of environmental factors that may con-
tribute to alterations to the microbiota in IBD, 
including diet, medication and environmental 
exposure. Such integration (omics and non-
omics data sets) for IBD will open up new thera-
peutic targets and mechanistic understanding of 
IBD.
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